ADVENZYMES Advanced Enzyme Technologies Q1 FY27 results (Apr–Jun 2026) and concall
Advanced Enzyme Technologies reported a softer Q1 FY27 with modest 2% YoY revenue growth to INR 1,898 million, impacted by an additional INR 100 million sales reversal and a 7% sequential decline. Profitability metrics saw compression, with EBITDA margin at 27% and PAT down 5% YoY. The company announced a buyback of INR 697 million and acquired full ownership of JC Biotech, while management expressed confidence in achieving double-digit revenue growth and margin recovery to 30-32% for the full year.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q1 FY27: revenue down 7.2%, net profit down 70.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 77 | 101 | 87 | 125 | 116 +51% | 96 −5% | 116 +33% | 116 −7% |
| EBITDA | 14 | 22 | 14 | 31 | 30 +114% | 23 +5% | 27 +93% | 30 −3% |
| Net profit | 9 | 15 | 11 | 74 | 22 +144% | 13 −13% | 22 +100% | 22 −70% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
